Facing limited viral vector manufacturing capacity, should companies consider further integrating their viral vector supply to address this issue? James Nanista and Josh Hunt of Adaptimmune reflect on the options.
Autologous cell therapies are becoming an increasingly established treatment option – particularly for patients with late-stage cancer. To deliver these therapies at an ever-increasing rate requires a robust supply chain, of which viral vectors are a critical component for many cell and gene therapy companies.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Traditionally, companies have sought to outsource the development and manufacture of vectors to a contract development and manufacturing organisation (CDMO). However, increasing demand from a growing market, logistics issues and manufacturing challenges all contribute to a less stable supply chain. Within recent years this situation has been further exacerbated by the COVID-19 pandemic: both directly, through viral vaccine manufacture; and indirectly, through instability in global supply chains.
An integrated vector supply, however, can help manage uncontrollable external factors by limiting supply chain uncertainty and allowing companies to respond in a more agile manner to challenges as they arise. To integrate vector supply, upfront challenges and costs include developing a scalable process and setting up a good manufacturing practice (GMP) manufacturing facility. However, these challenges are far outweighed by the long-term benefits of better meeting patient needs.
“An ever-expanding pipeline of products with 14 therapies (gene therapies, gene‑modified cell therapies and recombinant vector vaccines) currently marketed in the EU, Japan, US and UK, utilise viral vectors”
Using a viral vector for transgene delivery is commonplace across the cell and gene therapy industry. An ever-expanding pipeline of products with 14 therapies (gene therapies, gene‑modified cell therapies and recombinant vector vaccines) currently marketed in the EU, Japan, US and UK, utilise viral vectors – with an additional 3,000 therapies pending approval.1 This rising demand in turn places even greater pressure on a vector supply chain that currently does not have the capacity to support this.
An analysis performed at the end of 2019 concluded that demand for viral vectors would have surpassed CDMO capacity during 2020.2 However, this assessment has recently been altered with the emergence of the COVID-19 pandemic and its subsequent negative impact on manufacturing capacity. Capacity has been impacted by COVID-19 vaccine developers who are in direct competition with vaccines both in the commercial and development phases. Those available commercially include adenoviral-based vaccines by AstraZeneca and Johnson & Johnson. Concomitantly, general supply chain issues, such as plastics, single‑use tubing and bags that are used as standard, have also had an impact across the industry.
Given the extraneous demand, it could be asked why capacity has not kept pace as one would expect with other modalities. Two key differences limit industry’s capability:
A lack of standardised processes across the industry, incurring greater development costs and increased challenge to obtain regulatory approval
The fact that vector processes are also more difficult to scale up, requiring high-grade facilities and highly specialised personnel.
Alternatively, to mitigate some of the risks associated with outsourcing vector manufacturing to a CDMO, a company can manufacture vectors in-house, as taking this approach has numerous advantages. One of the most important for a fast-paced cell and gene therapy company is having greater control over a critical part of the supply chain by eliminating delays associated with securing manufacturing slots at a CDMO. This grants the business more agility in responding to changing needs and greater resilience to external shocks, such as the recent pandemic. Another factor in this enhanced adaptability is development of in-house expertise that enables more efficient interaction by simplifying communication channels. This also applies to conversations with regulators, a complex three-channel discussion involving the CDMO is not only inefficient but can also mean some nuances in feedback are not received by the sponsor. An integrated vector supply also supports regulatory submission through the greater product understanding gained by having better integration between the viral vector and the T-cell product in late-stage development activities. Once the product is approved, having an integrated vector supply means the business can better compete on cost. However, the greatest benefit is reduction of risk to patient supply, thus ensuring safe and timely delivery of treatment to patients.
Adaptimmune has successfully integrated its vector manufacturing. It is currently developing and manufacturing autologous cell therapies for clinical trials at numerous sites in North America and Europe, for a variety of solid tumour types, with the aim of commercial manufacture in 2023. Essentially, a patient’s white blood cells are collected in a clinical setting and sent to a centralised manufacturing facility where the T cells are isolated and transduced with lentiviral vectors to express the gene for an engineered T-cell receptor (SPEAR TCR). The cells are then expanded over a period of days, cryopreserved, and returned to the hospital where the cells are thawed and the patient lymphodepleted prior to infusion of the engineered T cells (see Figure 1).
Figure 1: The patient cell journey for AdaptImmune’s autologous SPEAR T-cell therapy products.
Building in-house vector supply
The first stage in bringing vector supply in-house was the development of a vector manufacturing process. Adopting the principles of quality by design (QbD) by carrying out pragmatic and smart experiments is critical to developing a successful and robust process. This approach simplifies later stages for both development and regulatory filings. It also helps with building a strong knowledge base of the process parameters and their potential impacts, which ultimately helps establish critical process parameter limits and prepares for characterisation. During development it is also beneficial to consider practical aspects of GMP manufacturing and develop a straightforward process, which can reduce the likelihood of deviations while maximising yields.
The first key step was developing a serum-free suspension-based process using stirred tank reactors. This process overcame the typical scale-up issues encountered in adherent systems at a manufacturing scale and dramatically increased yields. Combined with developing an effective purification process, a successful platform process allows Adaptimmune to manufacture lentiviral vectors in-house.
Following initial development, the lentiviral vector process was transferred into the GMP manufacturing facility. As a pre-revenue cell therapy company, Adaptimmune was able to utilise a module within the Cell and Gene Therapy Catapult site in Stevenage, UK, which provides GMP modular cleanrooms for developing large-scale manufacturing systems.
“Some key considerations for a GMP manufacturing suite include space utilisation, expected process workflow, operator headcount, materials quality and specifications, and documentation suitability for batch records and process descriptions with outlined unit operations.”
Some key considerations for a GMP manufacturing suite include space utilisation, expected process workflow, operator headcount, materials quality and specifications, and documentation suitability for batch records and process descriptions with outlined unit operations. These are just a few of the required considerations that must be signed off by regulatory bodies once all criteria have been met in establishing a GMP facility.
Technology transfer of the process from development to manufacturing involves generating a wide variety of documentation, data and training. Once this information has been generated and successfully handed over to the relevant teams, alongside any required training, a series of engineering runs can take place with the support of the Development and Quality Assurance teams. Upon their successful completion, the process can be considered transferred. Technology transfer is an inherently complex and time-consuming process but is sufficiently smoother when conducted internally as opposed to by a CDMO.
The entirety of development, technology transfer and early manufacturing batches has resulted in a high performing, cross‑functional group that works towards a common goal by utilising a wide variety of skills and expertise. This has been the cornerstone for developing a successful supply of in-house lentiviral vector.
References
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines [Internet]. Globaldata.com. 2021 [Cited 16 September 2022]. Available from: https://www.globaldata.com/store/report/viral-vector-contract-manufacturing-industry-analysis/
2. Rininger J, Fennell A, Schoukroun-Barnes L, et al. Capacity Analysis for Viral Vector Manufacturing – BioProcess International [Internet]. 2022 [Cited 16 September 2022]. Available from: https://bioprocessintl.com/manufacturing/emerging-therapeutics-manufacturing/capacity-analysis-for-viral-vector-manufacturing-is-there-enough/
James Nanista is a senior scientist in the Vector Process Development team at Adaptimmune. James has over six years of experience within industry with expertise in downstream processing for viral vectors. While working at Adaptimmune he has played a key role in the initial development of the lentiviral vector manufacturing process and its subsequent optimisation. He has also been heavily involved in ensuing tech transfer and implementation within the manufacturing environment. James holds a BSc in Biomedical Science.
Josh Hunt is a senior scientist in the Vector Process Development team at Adaptimmune with a primary focus on upstream processing. He has worked in the team for four years and has played a crucial role in the development and implementation of a lentiviral vector process into manufacturing, ensuring a suitable quality and product yield is achieved within a GMP environment to supply to clinical trials. Previous experience includes USP process development work on monoclonal antibodies, and work within a GMP manufacturing clean room for the purification of blood coagulation factors. Josh holds a BSc in Human Biology.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.